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Abstract
Ovarian cancer accounts for only 3% of all cancers in 
women, but it causes more deaths than any other gy-
necologic cancer. Treatment with chemotherapy and 
cytoreductive surgery shows a good response to the 
therapy. However, in a large proportion of the patients 
the tumor grows back within a few years. Cancer stem 
cells, that are less responsive to these treatments, are 
blamed for this recurrence of disease. Immune therapy 
either cellular or humoral is a novel concept to treat 
cancer. It is based on the notice that immune cells in-
vade the tumor. However, the tumor invest heavily to 
escape from immune elimination by recruiting several 
immune suppressive mechanisms. These processes are 
normally in place to limit excessive immune activation 
and prevent autoimmune phenomena. Here, we discuss 
current knowledge about the immune (suppressive) 
status in ovarian cancer. Moreover, we discuss the im-
munological targets of ovarian cancer stem cells.
© 2013 Baishideng. All rights reserved.
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Core tip: Ovarian cancer harbors, at a low frequency, 
cancer stem cells. Those cancer stem cells express 
stem cell specific antigens. Natural immunity against 
those antigens exists but is hampered by the suppres-
sive microenvironment that the tumor creates. Erasing 
this suppressive microenvironment will make immuno-
logical elimination of those cancer stem cells is an at-
tractive treatment option.
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EPITHELIAL OVARIAN CANCER
Ovarian cancer is the fourth leading cause of  death from 
cancer in women and the leading cause of  death from 
gynecological cancer. The lifetime risk to get this disease 
is 1 in 60 women in industrial countries but is less com-
mon in Asian and African women. Due to vague symp-
toms and adequate screening methods at the early stages, 
more than 60% of  the patients are diagnosed at advanced 
stage. Most patients respond well to primary treatment, 
either cytoreductive surgery followed by chemotherapy or 
chemotherapy followed by surgical removal of  remain-
ing tumor foci. However, 80% of  the patients diagnosed 
at late stage will eventually develop recurrent diseases, 
the survival is generally poor. The 5-year survival rates 
at stage Ⅲ and Ⅳ are 29% and 13%, respectively. The 
relapse of  tumor arises the question about the identity of  
the cells that give rise to the tumor and somehow escape 
from the first line treatment, reside in the body unde-
tected, and finally initiate malignant tumor growth in a 
suitable microenvironment.
Despite intense efforts to improve chemotherapy, e.g., 
the introduction of  paclitaxel, and to improve surgical 
techniques, over the past 20 years no significant progress 
has been made (Figure 1).
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Novel therapeutic approaches are urgently needed. 
Since ovarian cancer is immunogenic, immunotherapy 
should be further pursued and optimized. Stimulating the 
immune system to attack ovarian tumor is not a new con-
cept, during the last 20 years numerous immunological 
modalities were involved in clinical trials in ovarian can-
cer treatment[1]. Targeting a specific tumor antigen plays a 
decisive role in the success of  immunotherapy.
CANCER STEM CELLS
Tumors are composed of  phenotypically and functionally 
heterogeneous cells. There are two theories explaining 
how this heterogeneity arises[2,3]. According to the sto-
chastic model, tumor cells are biologically equivalent; vir-
tually every tumor cell is able to generate new tumor cells. 
In contrast, the hierarchy model postulates the existence 
of  tumorigenic as well as non-tumorigenic cells. Only a 
subset of  cells can initiate tumor growth, and these cells 
are considered as tumor-initiating cells (TICs) or cancer 
stem cells (CSCs). CSC is a relatively rare cancer cell that 
has the ability of  self-renewal giving rise to another ma-
lignant stem cell as well as a cell that undergoes massive 
proliferation and differentiation to give rise to the phe-
notypically and functionally more mature cancer cells[4,5]. 
The similarities of  CSCs and normal stem cells (NSCs) 
point to the origin of  CSCs. There are two hypotheses[6]. 
One states that CSCs can be derived from NSCs, so that 
they can make use of  the already active self-renewal ma-
chinery. Another assumes that the CSCs can be derived 
from progenitor cells by regaining the self-renewal capa-
bility. NSCs possess several unique properties. Their self-
renewal enables livelong maintenance of  all organs of  the 
body. In most cases NSC divide slowly. For hematopoi-
etic cells a doubling time of  30 d was reported[7]. How-
ever, for intestinal cells a doubling time of  less than 24 h 
was reported[8]. Those fast regenerating organs have stem 
cells that are continuously dividing. One of  properties 
of  NSC is the expression of  pumps of  the ATP binding 
cassette (ABC) superfamily[9-11]. Those pumps can remove 
toxic components from the cell. Likewise CSC also ex-
presses members of  the ABC family[10-19]. For melanoma 
ABC-B1 and ABC-B5 were reported while other tumors 
express other members[12,13]. This endows CSC with a 
nasty property. The pump is able to remove cytotoxic 
drugs that are given to patients to kill the tumor. Indeed, 
a common property of  CSC is their resistance against 
cytotoxic drugs, explaining the relapse that is seen in sev-
eral patients. Traditional therapies that kill primarily non-
tumorigenic cancer cells can shrink tumors, but will not 
cure the patient because the CSCs that survive the treat-
ment will regenerate the tumor. By prospectively identify-
ing and characterizing CSCs, it might be possible to iden-
tify more effective therapies[20-24]. CSCs can be eliminated 
by direct killing, or force them to differentiated cells or by 
destroying their niche[25]. Accordingly, targeting the CSCs 
has been put forward as such a new treatment modality 
for cancer immunotherapy[26,27]. Several studies described 
in the literature provide several clues for optimizing the 
immunotherapy against ovarian cancer.  
IDENTIFICATION AND 
CHARACTERIZATION 
The first experimental evidence suggests the existence 
of  CSC came from leukemia. Bonnet and co-workers 
demonstrated that human leukemias are driven by a small 
population of  leukemic stem cells capable of  transferring 
the disease to NOD/SCID mice[28]. This concept was ex-
tended to solid epithelial tumors by Al-Hajj and co-work-
ers, who demonstrated that a small population of  cells 
within breast cancer with stem cell properties, bearing the 
surface marker CD24lowCD44high[4]. Subsequently, CSCs 
are identified and prospectively isolated from a variety of  
epithelial cancers, including pancreas, colon and prostate 
cancers[29-40]. 
Ovarian CSC is responsible for ovarian tumor formation
The CSC hypothesis has recently also been explored in 
ovarian cancer. In 2008, Zhang et al[39] claimed that epi-
thelial ovarian cancers derive from a subpopulation of  
CD44+CD117+ cells. Ferrandina and Curley independent-
ly found that CD133 expression defines a tumor initiating 
subpopulation of  cells in human ovarian cancer[41,42]. Gao 
and co-workers reported that CD24 could be utilized as 
a surface marker to enrich for ovarian CSCs[32]. Ovarian 
CSCs were also detected in the so-called side population, 
which are tumorigenic and chemoresistant[38,43,44]. More-
over, Stewart et al[45] established a quantitative assay that 
enables characterization of  TICs from serous ovarian 
cancer, and they also found that the tumor initiating cell 
phenotype is heterogeneous across patients. And recently, 
a gene involved in maintaining stem cell pluripotency, 
Nanog, was proved to be expressed by ovarian tumor 
cells, and positive Nanog expression indicates poor pro-
gression of  patients with ovarian serous carcinoma[46].
As described above, increasing experimental evidence 
suggests that TICs may play a decisive role in the initia-
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Figure 1  Survival of patients diagnosed with ovarian carcinoma. The per-
centage of survival after diagnosis is not significantly increased in the past 20 yr 
(Source from Integraal Kanker Centrum, The Netherlands) .
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tion and progression of  tumors[4,29-31,35-39,46]. However, 
TICs with distinct tumorigenic abilities were identi-
fied[31,47,48], as well as large variation in their frequency[49,50]. 
TICs appear not to be a stable entity but show quite 
some plasticity[2,51-54]. Recently, it was described that the 
TIC compartment can be subdivided into long-term 
TICs, tumor transient amplifying cells as well as delayed 
contributing TICs[48]. Only the long-term TICs are capa-
ble of  maintaining tumor formation in serial xenografts, 
and these cells are considered as cancer stem cells. 
Phenotypic heterogeneity of ovarian CSCs
CSCs are operationally defined as tumor initiating cells 
because the CSC assays rely heavily on xenotransplan-
tation[55]. Although it was proven that frequency and 
tumorigenic ability of  melanoma CSCs that can be de-
tected after xenotransplantation were highly dependent 
on experimental design[50,56], current studies on CSCs all 
use immunodeficient mice models to check whether pu-
tative CSCs can generate secondary tumors in vivo. And 
using this method, phenotypically diverse ovarian CSC 
populations have been characterized and isolated from 
both patient material and immortalized tumor cell lines 
with variable stem cell markers[32,36,38,41,42,46,57,58]. However, 
due to the fact that a large number of  cells was needed to 
establish a secondary tumor in immunodeficient mice, it 
is assumed that ovarian CSCs were just enriched in those 
cell populations[59]. Also, it was questionable whether tu-
mor cell lines can represent the status of  primary tumor 
cells. Moreover, due to the heterogeneity among indi-
viduals, it is important to test CSC markers in significant 
numbers of  patients.
The expression of  well-known CSC markers, includ-
ing, CD44, CD117, CD133, CD24, ABCG2 and aldehyde 
dehydrogenase (ALDH), on tumor and ascites derived 
cells from patients diagnosed with ovarian cancer is very 
diverse and is patient-dependent, and no correlation was 
found between marker expression and tumor histological 
subtype[60]. In line with these data, another study investi-
gated epithelial and mesenchymal markers expressed by 
primary ovarian tumors, and they also showed different 
phenotypic features and expression levels of  those mark-
ers in different cellular subsets within tumors[59]. Addi-
tionally, it has been reported that the CSC marker ALDH 
show distinct expression pattern in human epithelial can-
cers, and it can only be used to isolate CSCs for tumors 
whose corresponding normal tissues express low levels 
of  ALDH[61]. Also CD133 as a marker to identify ovarian 
CSCs has been questioned, since tumor initiating activi-
ties have been detected in both CD133+ and CD133- 
fractions from primary ovarian masses, and CD133+ cell 
frequency varies between patients[45]. Similar doubts of  
CD133 as a putative CSC marker has been reported in 
colon cancer and melanoma[56]. Moreover, phenotypic 
heterogeneity of  breast CSCs was also reported[34,40,62]. 
Taken together, these data suggest that CSC phenotypes 
are heterogeneous, and experimental variables as well as 
xenograft recipients can dramatically influence CSC fre-
quency[45]. So far a clear set of  marker proteins remain to 
be identified to target ovarian CSCs.
For better recognition of  CSCs, better experimental 
methods need to be established. One way to identify CSC 
is to focus on genes involved in stem cell pluripotency, 
because those genes may be involved in establishment of  
tumors and may be inherited by their malignant counter-
parts. Four genes are required for induction of  pluripo-
tent stem cells from mouse embryonic or adult fibroblasts 
in vitro, including Oct4, c-Myc, Sox2 and Klf4[63]. A rare 
cell population, in ovarian tumor tissue as well as ascites, 
expressing Oct4, Nanog and c-Myc was found. Oct4 ex-
pression is crucial for the self-renewing and maintenance 
of  pluripotent properties of  embryonic stem (ES) cells 
[64,65]. The expression of  Oct4A indicates that the cells 
are undifferentiated[66]. Recently, abnormal Oct4 expres-
sion level was correlated to several cancers[67-69]. The two 
isoforms of  Oct4, Oct4A and Oct4B, differ in their abil-
ity to confer self-renewal, only Oct4A can sustain stem 
cell properties[70,71]. Several studies have shown that the 
different isoforms and Oct4 may lead to false positive 
signals during RT-PCR analysis[72,73]. In order to rule out 
this, a primer set was described to distinguish the Oct4A 
from Oct4B and Oct4 pseudogenes[73]. Oct4A mRNA 
expression was detected by us in ascites-derived tumor 
cells from all patients tested, regardless of  histological 
subtypes. The c-Myc protein is normally expressed in the 
nucleus and is virtually undetectable in quiescent cells. It 
contributes to the long-term maintenance of  the ES cell 
phenotype and is upregulated in many types of  malignant 
human cancers[74]. Moreover, Nanog also sustains ES cell 
pluripotency[75]. Oct4 and Nanog were described to be 
higher expressed in side population cells obtained from 
ovarian cancer cell lines than the bulk of  the cells[76], con-
firming the expression of  stem cell markers as described 
here. To sum up, expression of  these genes suggests 
that those cells are the primitive CSC for ovarian cancer, 
because all genes needed for reprogramming to induce 
pluripotent stem are present in the same cell.
According to the hierarchy tumor model, the most 
“primitive’’ CSCs are able to self-renew, and develop into 
more differentiated cells like so-called progenitor cells or 
CSC-derived transit-amplifying cells, which are not able 
to self-renew but can generate new tumor cells to sup-
port tumor growth[34,48]. In order to adapt to different host 
microenvironments, CSC-derived progenitors may differ 
in their phenotypes and functions and in turn differenti-
ate into phenotypically and functionally heterogeneous 
tumor cells[77]. And a different differentiation status might 
be generated also to adapt the complicated tumor growth 
environment[78]. These indicate that CSCs and their prog-
enies may differ between different patient tumors and may 
be able to change during tumor progression[55]. Collective-
ly, these data may explain why the expression of  putative 
CSC phenotypes are heterogeneous among patients with 
ovarian cancer and why accumulating evidence shows that 
solid tumors are initiated by heterogeneous populations 
of  CSCs, and each CSC subset responsible for distinct 
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functions in tumor progression[33,34,40,45,47,48,50,79-83][Engh, 
2011 #756].
Although CSC phenotypes are heterogeneous, cur-
rent studies suggest ovarian tumor conforms to the CSC 
hypothesis[45,59], and in this scenario, if  the most primitive 
Oct4-expressing CSC population is eliminated specifi-
cally, the tumor will lose its feeding and eventually fade 
away (Figure 2).
Phenotypic plasticity of ovarian tumor cells 
CSC may not be a stable entity. Plasticity describes the 
dedifferentiation potential of  more differentiated cancer 
cells to acquire stem cell phenotype and characteristics, 
which further contribute to CSC heterogeneity, and 
which is an important determinant of  the prognosis of  
tumors[55,84,85]. Thus plasticity in CSCs and their prog-
enies make the situation more complex[51,59]. Two c-Myc 
expressing populations were found; one is only highly 
positive for c-Myc, the other also express Oct4. The ire-
lationship between these two subpopulations remains to 
be investigated. We argue that those intermediate c-Myc+ 
cells are more differentiated cells than c-Myc+ Oct4+ 
cells, since in some cases they were not able to survive in 
serum-free medium. Also, it is possible that the c-Myc+ 
cells somehow regain Oct4A expression and become a 
primitive CSC. In fact, phenotypic plasticity of  ovarian 
tumor cells was detected under certain circumstances, e.g., 
stress created by starvation or co-culture with either epi-
thelial or mesenchymal cells in vitro[59]. 
In line with this, plasticity has been described in other 
tumor stem cell studies, showing that non-tumorigenic 
cells can convert to a tumorigenic cell[50,86,87]. For instance, 
knocking down of  JARID1B in slow cycling melanoma 
cells exhausted the tumor, however, expression of  JA-
RID1B is dynamic since negative cells can become JA-
RID1B positive[47]. This indicates that the cancer cells 
might reversibly transit between tumorigenic and non-
tumorigenic status, generate reversible heterogeneity[85,88]. 
In addition to tumor cells, plasticity was also described in 
normal development procedures. Endothelial cells could 
simply be converted into multipotent stem-like cells by 
Transforming growth factor β2 or Bone morphogenetic 
protein 4[89]. Also in spermatogonial development more 
differentiated cells can go back to the stem cell state 
when the stem cell niche is emptied and the number of  
stem cells is decreased. In this way the normal number of  
stem cells is recovered by differentiated cells that regain 
stem cell properties[90]. Plasticity would have major im-
plications for the CSC model and for future therapeutic 
approaches, as discussed in[52]. 
INTERPLAY BETWEEN TUMOR AND THE 
IMMUNE SYSTEM
The immune system affects cancer development and pro-
gression. Before the tumor cells cause clinically detectable 
disease, they have already resided in the body for a while. 
The immune system can recognize and interact with 
the transformed cells before and after the formation of  
tumormass; this process is termed “cancer immunoedit-
ing’’. Cancer immunoediting consists of  three distinct 
phases: elimination, equilibrium and escape[91,92]. During 
the elimination phase, tumor specific immune cells and 
molecules are recruited to the tumor site and destroy the 
developing tumor cells. The equilibrium phase is a dy-
namic state; the interaction between tumor growth and 
immune prevention represents a type of  tumor dorman-
cy, in which tumor outgrowth is also limited by the im-
mune system[93]. Meanwhile, due to the immune selection, 
some malignant cell can acquire the ability to circumvent 
immune recognition, or no longer sensitive to immune 
effector mechanisms, and escape. And then their growth 
is no longer blocked by the host immunity anymore. In 
addition, the malignant tumor cells can even manipulate 
the immune system to promote their own growth[91,92]. 
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Immune elimination of tumors 
The effectors mechanisms of  both cell-mediated immu-
nity and humoral immunity have been shown to kill tu-
mors in vitro. In several cases also in vivo killing of  tumor 
cells was observed. During the elimination phase of  can-
cer immunoediting, different types of  immune cells are 
recruited to the tumor site, including T cells, antibody-
secreting B cells, different subsets of  dendritic cells (DCs), 
tumor-associated macrophages (TAMs), myeloid-derived 
suppression cells (MDSCs), Th17 cells, natural killer (NK) 
cells, NK T cells and γδT cells[94,95]. And those intratu-
moral T cells were functionally active since interleukin-2 
(IL-2) and interferon-γ (IFN-γ) was produced, which may 
enhance T cell proliferation and anti-tumor immunity[96,97].
An effective antitumor immune response is direct 
killing of  tumor cells by CD8+ cytotoxic T lymphocytes 
(CTLs), which recognize tumor antigens presented by 
MHC Ⅰ molecules. CD8+ T cell responses specific for 
tumor antigens may require cross-presentation of  the 
tumor antigens by professional antigen presenting cells 
(APCs), such as DCs. Most tumor cells do not express 
the co-stimulatory molecules needed to initiate T cell 
responses or the class Ⅱ MHC molecules needed to 
stimulate helper T cells that promote the differentiation 
of  CD8+ T cells. It is possible that tumor cells or their 
antigens are ingested by host DCs, the tumor antigens 
are then processed inside the DCs, and peptides derived 
from these antigens are displayed bound to class Ⅰ MHC 
molecules for recognition by CD8+ T cells. The APCs 
expressing co-stimulatory molecules that provide the sig-
nals needed for differentiation of  naïve CD8+ T cells into 
anti-tumor effector CTLs, and the APCs express class 
Ⅱ MHC molecules that may present internalized tumor 
antigens and activate CD4+ helper T cells as well. Once 
effector CTLs are generated, they are able to recognize 
and kill the tumor cells without a requirement for co-
stimulation. CTLs mediate lysis of  target cells by two ma-
jor mechanisms, the predominant mechanism appears to 
be perforin-granzyme-dependent, and the other is FasL 
dependent[98,99]. The ability of  CTLs to provide effective 
anti-tumor immunity in vivo is most clearly seen in animal 
experiments. However, tumor-specific CTLs can be iso-
lated from animals and humans with established tumors, 
such as melanomas[100].
The importance of  CD4+ helper T cells in tumor im-
munity is less clear. CD4+ cells may play a role in anti-
tumor immune responses by providing cytokines for 
effective CTL development. In addition, CD4+ T cells 
specific for tumor antigens may secrete cytokines, such as 
tumor necrosis factor (TNF) and IFN-γ, that can increase 
tumor cell class I MHC expression and sensitivity to lysis 
by CTLs. IFN- γ may also activate macrophages to kill tu-
mor cells. In addition to T cells, tumor-bearing hosts may 
produce antibodies against various tumor antigens[101-104]. 
Whereas it has also been documented that CD4 T cells 
can be more effective than CD8 T cells in tumor killing 
in tumor bearing mice[105]. Moreover, NK cells may kill 
many types of  tumors, especially “missing’’ cells that have 
reduced class I MHC expression and can escape killing 
by CTLs[106,107]. CD4+ T cells cooperate with NK cells to 
accomplish the maximum tumor killing[105]. Macrophages 
can kill many tumor cells more efficiently than they can 
kill normal cells[108]. Several studies showed the existence 
of  tumor infiltrating T cells in ovarian cancer associated 
with favorable clinical outcome[109,110]. Distribution of  
tumor infiltrating lymphocytes (TILs) were studied in 
patients with late stage ovarian cancer, CD3+ T cells were 
detected in more than 50% of  the patients and CD4+ 
and CD8+ T cells were either both present or absent. The 
presence of  TILs correlates with a better 5 year survival 
as well as progression-free survival[39]. It has also been 
documented that patients with higher TIL counts showed 
improved overall survival than patients with lower TIL 
counts[111]. Moreover, Sato and co-workers demonstrated 
intraepithelial CD8+ TILs and the high CD8+ TIL/ 
Treg ratio indicates better survival of  ovarian cancer pa-
tients[112]. 
Immune reactivity towards CSCs
When the immune system is directed to eliminate the 
CSC, it will also destroy CSC reverting from more dif-
ferentiated progeny. We consider Oct4 as a suitable anti-
gen for immunological targeting ovarian CSCs, since it is 
neither expressed in normal adult stem cells nor somatic 
cells. Once the progenitors re-express Oct4 and become 
CSCs, they can be recognized and eliminated by Oct4-
reactive T cells. Removing of  the CSCs from the pool 
will diminish the feeding of  more mature tumor cells. 
Further understanding of  the relationship between CSCs 
and their differentiated progenies can help us to develop 
better immunotherapeutic strategies that can prevent the 
emergence of  tumor cell variants that are capable of  gen-
erate a new tumor and metastases[55,113]. 
OCT4-REACTIVE T CELLS ARE 
DETECTABLE 
Naturally occurring T cells directed against tumor-associ-
ated antigens (TAAs) can be frequently detected in cancer 
patients (reviewed in[114]). Amazingly, Oct4 reactive CD4+ 
as well as CD8+ T cells were detected in both healthy 
people and patients with ovarian cancer[115]. This find-
ing suggests that the host immune system has the ability 
to target the primitive ovarian CSCs. The frequency of  
Oct4 specific T cell was low in peripheral blood, while it 
was higher in the ascites of  patients. This means those 
cells are either recruited to the tumor or proliferate upon 
exposure to Oct4. Moreover, lymphocytes isolated from 
ascites from patients with ovarian tumor contained Oct4 
specific T-cells. It was shown that Oct4-reactive CD8+ 
T cells produce IFN-γ-inducible protein 10 (IP-10) and 
IFN-γ, and were capable of  proliferation upon Oct4 pep-
tide loaded or Oct4 mRNA pulsed dendritic cell stimula-
tion. The CD8+ cytotoxic T cells were able to release ly-
sosomal components as indicated by CD107a expression. 
Moreover, Oct4-reactive CD4+ T cells were also detected, 
October 26, 2013|Volume 5|Issue 4|WJSC|www.wjgnet.com 153
Di J et al . Immune elimination of cancer stem cells
and also capable of  proliferating upon stimulation. These 
results proved the existence of  anti-CSC specific T cells 
in patients with ovarian cancer. 
Natural immunity against genes involved in pluripo-
tency has been shown. Dhodapkar et al[115] claim the Oct4 
responsive T cells were detected in PBMCs from 83% of  
healthy donors, although they showed the Oct4-specific 
cells were CD4+ T cells. They also found 38% of  patients 
with germ-cell tumors had measurable Oct4-specific T 
cell immunity at baseline, and after chemotherapy, 83% 
of  the patients developed Oct4-reactive T cells.  Also, it 
has been documented that CD8+ Sox2-specific T cells 
were frequently detected in patients with monoclonal 
gammopathy of  undetermined significance (MGUS). 
MGUS is a precursor lesion to myeloma, whereas Sox2-
specific T cell immunity was not detectable in patients 
with myeloma[116]. 
Taken together, these data indicate that the ovarian 
CSCs are prone to immunological attack because CSC 
specific T cells are present in the T cell repertoire (Figure 
3). Meanwhile, this raises the question about why CSCs 
and their progenies escape from immune elimination, and 
why the already activated Oct4-reactive memory T cells 
do not kill those cells.
Immune escape by tumors
Many malignant tumors possess mechanisms that enable 
them to disturb the balance in the equilibrium phase and 
shift to escape phase, including down-regulation of  MHC 
Ⅰ expression on tumor cells, loss or hidden of  tumor-
antigen expression, production of  immune suppressive 
molecules, and inhibition of  co-stimulatory or MHC Ⅱ 
molecules expression on APCs, leading to immunologic 
tolerance[92,117,118]. Tumors escape not only from the host 
immune system, but also effectively benefit from infil-
trating cells and create a microenvironment that favors 
its progression by modifying TIL functions[119]. Ovarian 
tumor can effectively create its suppressive microenvi-
ronment. Curiel et al[120] showed the first evidence that 
tumor associated CD4+CD25+ regulatory T cells (Treg) 
were correlated with a poor clinical prognosis of  ovarian 
cancer. They showed the presence of  Treg in both tumor 
tissue and malignant ascites, and also proved that tumor 
cells and microenvironmental macrophages produced the 
chemokine CCL22, which attracted Tregs to the tumor 
site. Tumor infiltrating Tregs suppress tumor-specific T 
cell immunity by blocking T cell proliferation as well as 
IFN-γ and IL-2 production. Similarly, Woo et al[121] found 
that CD4+CD25+ Tregs contribute to CD8+ T cell dys-
function by secreting the immunosuppressive cytokine 
transforming growth factor-β (TGF-β). Later on, fork-
head box protein-3 (FoxP3) expressing Tregs were also 
detected and emerged as an independent prognostic fac-
tor for both poor progression-free and overall survival[122]. 
Conrad et al. demonstrated that majority of  these FoxP3+ 
Tregs accumulated nearby the tumor and also express in-
ducible co-stimulator (ICOS)[123]. The expansion and im-
munosuppressive function of  these FoxP3+ICOS+ Treg 
cells are dependent on their interaction with plasmacytoid 
DCs (pDCs) which provide ICOS-ligand (ICOS-L) stim-
ulation. The presence of  immature pDCs was also found 
in the vicinity of  ovarian tumor and associated with 
poor clinical outcome of  patients with ovarian tumor[124]. 
pDCs are recruited by CXCL12 produced by tumor cells 
and produce type Ⅰ IFN in response to toll-like receptor 
(TLR) ligand triggering[125,126]. In addition to CD4+ Tregs, 
CD8+ Tregs also exist in ascites produced by malignant 
ovarian tumor. Wei et al. showed that tumor pDCs in-
duce suppressive CD8+ Tregs in ascites. These CD8+ 
Tregs inhibit T cell proliferation and IFN-γ production, 
while they induce IL-10 production[126]. Moreover, ovar-
ian tumor infiltrating DCs express programmed death 1 
(PD-1), which interacts with B7-H1 on tumor-associated 
macrophages. This reaction can lead to suppressed NFκB 
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Regain self-renewal ability
Express Oct4
Kill
Eventually die
Figure 3  Hypothesis of specific targeting of primitive can-
cer stem cells. In a non-immunosuppressive tumor microen-
vironment, Oct4-specific T cells (αOct4 T cell) can recognize 
the primitive cancer stem cells (CSCs). and destroy them. 
Progenitor cells (Pro) differentiate to more mature tumor cells 
and will eventually undergo apoptosis or necrosis. Once some 
progenitors regain the self-renewal machinery and re-express 
Oct4 to become a CSC, T cells will also eliminate it. In this way, 
the tumor loses its ability to generate new tumor cells.
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activation and downregulated co-stimulatory molecule 
expression on DCs[127] (Figure 4).
Ovarian tumor infiltrating T cells are anergic
A remarkable characteristic of  ovarian cancer is the typi-
cal metastasis behavior. Metastases are found but hardly 
in other organs. As the tumor spreads in a diffuse intra-
abdominal fashion and even after recurrence, it is in most 
cases confined to the peritoneal cavity. There are several 
papers that report the presence of  metalloproteases in 
ascites[128-130]. Those enzymes are found in metastasizing 
tumors by chopping tissues to make room for the metas-
tasis. Moreover, ovarian tumors orchestrate suppressive 
mechanisms that enable them to evade or resist host im-
mune responses[131-135]. The fact that CTLs against human 
tumors can be easily generated in vitro using peripheral 
blood lymphocytes indicates that the tumor microenvi-
ronment has immunosuppressive capacities[131]. Tumor 
infiltrating immune cells together with fibroblasts and 
extracellular matrix form a scaffold supporting tumor cell 
expansion, contribute to establish an inflammatory milieu 
that nourishes the tumor and promotes its growth[131,136]. 
And apparently, the weak anti-CSC immunity generated 
by Oct4-reactive T cells is counterbalanced (Figure 5). 
Collectively, this metastasis behavior suggest that as soon 
as tumor cells escape from the immune suppressive mi-
croenvironment in the peritoneal cavity and enter sites 
where full immune responses are possible in the periph-
ery, they cannot survive[132,134,137]. This opens enormous 
possibilities to treat patients by boosting the immune 
response.
The assumption that without this suppressive mi-
croenvironment the immune system is able to eradicate 
tumor cells needs further prove. Furthermore, as argued 
for immunotherapy, only boosting the antitumor immune 
response is not enough. It is of  great importance to “re-
pair’’ the already existing tumor specific T cells in vivo. It 
was found that ovarian tumor infiltrating lymphocytes 
fail to proliferate in response to CD3/CD28 stimulation 
and adding IL-2 cannot reverse this unresponsiveness. 
The inhibited T cell proliferation was due to reduced 
cyclin E expression (unpublished data). So even though 
the host immune system can recognize the tumor, they 
lack the ability to eliminate it. The observed effects were 
reversible after culture of  the cells ex-vivo for 10 d. This 
demonstrates that the impaired functions are reversible 
and can be repaired. The results are in line with recent 
findings from other groups proved that TIL isolated from 
melanoma, oral carcinoma, colorectal carcinomas were 
also functionally impaired, as manifested by decreased 
proliferative responses and decreased ability to medi-
ate cytotoxicity[138]. Abnormalities in signal transduction 
molecules associated with reduced expression of  T-cell 
receptor (TCR) ζ chain[139] and/or hampered Fas/FasL 
signaling pathway[140]. Moreover, it has been shown that T 
cells isolated from ascites of  patients with ovarian tumor 
were deficient in expression of  ζ chain, lower basal lev-
els of  protein tyrosine phosphorylation, altered patterns 
of  protein phosphorylation when stimulated via surface 
CD3 or CD16, and declined expression and kinase activ-
ity of  p56lck. These deficiencies in expression and func-
tion of  signaling molecules were associated with reduced 
proliferation and an altered profile of  cytokine secretion 
by the NK or T cells isolated from ascites and stimu-
lated with IL-2 or by cross-linking of  surface CD3[141]. 
In addition, tumor-associated CD8+ T cells might be 
dysfunctional due to upregulation of  programmed death 
1 (PD-1) and T cell immunoglobulin and mucin-domain-
containing molecule 3 (Tim-3)[142,143]. We could not detect 
PD-1 expression in ascites-derived lymphocytes, how-
ever, both ascitic CD4+ and CD8+ cells showed up-
regulation of  Tim-3 (Figure 6). These findings indicate 
that infiltrated immune cells are not only suppressed, 
but also impaired in their signaling pathways resulting 
from the yet unknown factors present in tumor associ-
ated ascites. 
Furthermore, except for harming of  immune cells, 
ovarian cancer cells also secrete immunosuppressive and 
pro-inflammatory cytokines into the tumor microenvi-
ronment to support tumor growth[144,145]. Previous studies 
demonstrated that IL-6 is significantly increased in cyst 
fluid, serum as well as ascites of  patient with advanced 
Trafficking
Tumor cells
CCL22
Angiogenic
IL-10 TGF-β VEGF
TNF-α 
IL-8
Dysfunctional
Induction
Expansion
Figure 4  Immune-suppressive pathways in 
ovarian cancer. Tregs are attracted to the tumor 
environment by CCL22, secreted by the tumor. 
The tumor microenvironment expresses molecules 
that can convert functional antigen presenting cells 
(APCs) into dysfunctional ones. These dysfunction-
al APCs in turn stimulate Treg differentiation and 
expansion. pDCs are also present in the tumor en-
vironment and stimulate tumor growth by releasing 
tumor necrosis factor-α and interleukin-8. (modified 
from[132]). pDCs also facilitate immunosuppressive 
function of FoxP3+ICOS+Treg[123].
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ovarian cancer, and associated with poor prognosis[144,146]. 
IL-6 is a pro-inflammatory cytokine. It has multiple ef-
fects on T cell function, and it has already been reported 
to be an important factor in promoting the progression 
of  epithelial of  ovarian cancer[147]. IL-6 also plays a role 
in enhancing tumor growth by inducing abnormal c-Myc 
expression in vitro. It has been shown that IL-6 can in-
duce c-Myc translation in multiple myeloma cells and 
meanwhile c-Myc is shuttled to cytoplasm by the RNA-
binding protein, hnRNP A1[148]. Our research demon-
strated that c-Myc was expressed in both nucleus and 
cytoplasm in ovarian tumor tissue as well as ascitic cells, 
while c-Myc is only expressed in the nucleus of  normal 
stem cells. Similarly, except for being expressed in the 
nucleus, c-Myc was also detected in the cytoplasm of  
leukemia patients[149]. Regulation of  stem cell genes or 
even tumor development by cytokine indicates a strong 
correlation between the tumor and its microenvironment. 
Taken together, these results indicate that in addition to 
its suppressive property, the tumor successfully creates a 
favorable microenvironment to support tumor growth.
In conclusion, ovarian cancer is an extremely compli-
cated disease, because the tumor growth might be driven 
by heterogeneous CSCs and multiple immunosuppressive 
Tumor microenvironment
Lipid 
metabolites
Peripheral blood
Tumor cell Cytokines Figure 5  Dysfunctional immune system in peritoneal 
cavity of patients with ovarian cancer. Many types 
of immune cells are recruited to the ovarian tumor site, 
including regulatory T cells (Treg), dendritic cells (DC), 
tissue associated macrophages (TAM) myeloid derived 
suppressor cells (MDSC)[155], plasmacytoid DCs (pDC), 
natural killer cells and T cells (CD4, CD8). Once being 
recruited, most cells function abnormally and become 
immune suppressive. T cells specific for Oct4 (αOct4 
T cell), CD4+ T cells, CD8+ T cells are damaged, due to 
dysfunctional DCs, pDCs and suppressive Tregs. Also the 
secretion of immune suppressive cytokines and lipid me-
tabolites contribute to establish such an immunosuppres-
sive tumor microenvironment, and may also be required 
for cancer stem cells (CSCs) maintenance. So even if the 
CSC is recognized, T cells lack the ability to eliminate it. 
Whereas such suppression mechanisms are not opera-
tive in the peripheral blood of the patients, once the CSC 
migrates to the peripheral, it is killed.
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Figure 6  PD-1 and Tim-3 expression by ascitic lymphocytes from patients with ovarian cancer. PD-1 expression was undetectable in ascitic lymphocytes. Com-
pare to isotype control, peripheral blood lymphocyte (PBL) from healthy express 2% Tim-3, ascitic CD4+ and CD8+ cells express four times more Tim-3 than control PBL.
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mechanisms are functional in the abdomen. To enable an 
immunological attack on CSC either the response has to 
strengthened or the immunosuppressive milieu has to be 
reversed or both.  
FUTURE PERSPECTIVES
For future studies, it is of  great importance to investigate 
how somatic cells are reprogrammed in vivo to become 
malignant pluripotent cells, and how the self-renewal 
pathways are orchestrated in such transformed cells. 
Furthermore, it remains unclear why the pluripotent 
genes were upregulated in a small subset of  tumor cells. 
We sequenced both Oct4 and c-Myc isolated from ovar-
ian patient ascitic cells, however, no mutation was found 
(unpublished data). It is important to elucidate what 
went wrong in the self-renewal pathways in the patients 
and why. Understanding this might help to stop tumor 
growth before it happens. 
Another challenge is how to boost the favorable host 
immune response in the suppressive tumor microenvi-
ronment and train the immune system to fight against 
ovarian cancer. To overcome this, it is of  great impor-
tance to determine the mechanisms that contribute to 
protective immune responses against tumors and to en-
hance these effector mechanisms in a tumor specific way. 
And apparently, only boost the immune system is not 
enough to eliminate tumors, due to functional crippling 
of  TILs. 
Moreover, the role of  ascites in tumor progression 
remains to be elucidated. Ascitic fluid is produced by 
ovarian tumor. The cellular fraction of  ascites consists of  
tumor cells, lymphocytes and mesothelial cells; and the 
acellular fraction harbors cytokines, growth factors, bio-
active lipids, angiogenic factors, and extracellular matrix 
constituents[150-152]. Although the role of  ascites as tumor 
cell microenvironment remains poorly understood, re-
cent research suggests that it may affect cell growth, 
invasion and induction of  resistance of  ovarian cancer 
cells and thus may play a decisive role in ovarian tumor 
progression[153]. 
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